Released May 9, 2018, before the open
10-Q filed May 9, 2018, 39 days after period end · 0001144204-18-026625
Q1 2018 · 10-Q
Revenue$4.55M$4.55M +57.6% vs Q1 2017+5.8% vs Q4 2017
Net Income-$7.24M-$7.24M N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.50-$0.50 N/M vs Q1 2017no prior Q4 2017 on file
Gross Profit$1,629,000+103.4%
Operating Income-$5,151,000N/M
Operating Cash Flow-$9,413,000N/M
Free Cash Flowderived-$9,662,000N/M
Margins · derived
Gross margin35.8%+8.1 pt vs Q1 2017
Operating margin-113.1%+107.2 pt vs Q1 2017
Net margin-159.0%+1888.4 pt vs Q1 2017
What the release said
The release
Same quarter
| Metric | Q1 2018 | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|---|
| Revenue | $4.55M | $2.89M | $679.00K | $1.69M |
| Net Income | -$7.24M | -$59.15M | -$8.60M | -$5.97M |
| EPS Diluted | -$0.50 | -$0.48 | -$0.09 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR